Fujioka Ken
Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, California 92130, USA.
Obes Res. 2002 Dec;10 Suppl 2:116S-123S. doi: 10.1038/oby.2002.204.
The successful management of obesity requires a long-term approach that is tailored to an individual's lifestyle and needs. Initial treatment should focus on lifestyle modifications-dietary interventions and increased physical activity-with behavioral modification strategies used adjunctively. Several antiobesity drugs are approved by the Food and Drug Administration for use in obese patients, as well as in overweight individuals with at least one obesity-related comorbidity. Most are approved only for short-term weight loss, but sibutramine and orlistat are approved for long-term weight loss and maintenance. In addition to weight reduction, in clinical trials these drugs provided beneficial actions on several cardiovascular risk factors. Several other drugs currently approved for other uses show promise in their ability to cause weight loss. Surgical options should be reserved for severely obese patients with significant medical comorbidities or physical conditions.
肥胖的成功管理需要一种长期的方法,该方法要根据个人的生活方式和需求进行调整。初始治疗应侧重于生活方式的改变——饮食干预和增加体力活动——并辅助使用行为改变策略。几种抗肥胖药物已获美国食品药品监督管理局批准用于肥胖患者以及至少有一种与肥胖相关合并症的超重个体。大多数药物仅被批准用于短期减肥,但西布曲明和奥利司他被批准用于长期减肥和维持体重。除了减轻体重外,在临床试验中,这些药物对几种心血管危险因素也有有益作用。目前批准用于其他用途的其他几种药物在导致体重减轻的能力方面显示出前景。手术选择应保留给患有严重医疗合并症或身体状况的重度肥胖患者。